Anton Hagenbeek, MD, PhD from the University of Amsterdam, Amsterdam, Netherlands talks about the issue of drug costs in oncology. Drug combinations are effective but particulalry costly according to Prof. Hagenbeek. He argues that there is an urgent need to talk to the biotech companies producing the drugs and to agree on transparent pricing of these drugs and socially acceptable profit margins.
Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
The issue of drug cost: transparent pricing and acceptable profit margins
